Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma

Immacolata Attolico(Ospedale San Carlo), Attilio Olivieri(Ospedali Riuniti di Ancona), Sabrina Coluzzi(Ospedale San Carlo), Roberta Nuccorini(Ospedale San Carlo), Angelo Ostuni(World Health Organization Regional Office for South-East Asia), Pasquale Iacopino(Martin University), Vincenzo Pavone, Giuseppe Milone(University of Catania), Alessandra Crescimanno(La Maddalena), Patrizia Tedeschi(Ferrarotto Hospital), Massimo Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Maurizio Musso(La Maddalena), Elvira Di Nardo(University of Basilicata), Bernardo Rossini(Istituto Tumori Bari), Sara Pasquina Pascale(Ospedale San Carlo)
Transplantation and Cellular Therapy
July 26, 2011
10.1016/j.bbmt.2011.07.014
Cited by 74

Related Papers

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
|Blood|2008|253
Autologous hematopoietic stem cell transplantation in multiple sclerosis
|Neurology|2015|247
<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres
|British Journal of Haematology|2002|146
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays
|Leukemia|2011|69
Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
|Clinical Cancer Research|2013|68